patent/CN-104903450-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104903450-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96d79108d0eb162065256a81f897fd8b
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
filingDate	2013-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72ff5f6a71c081b25ab13a1ebb585336 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b0006f1adf612149085d76ceb1191d6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da139ccbc6ec62ae92bfdb8e368b048b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2443157cd3f4197b4367f0acfc8c5577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1331d9165bb35112a9bf8fb157fb9ce
publicationDate	2015-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CN-104903450-A
titleOfInvention	Dosing and Administration of Oligonucleotide Cancer Therapies
abstract	The present invention relates to cancer therapies, compositions and methods of using them. In particular, the invention provides methods of administering and administering cancer therapies comprising administering oligomers and liposomal formulations of oligomers, wherein the cancer is mediated by the bcl-2 oncogene. In some aspects, the oligomers and liposomal formulations of the oligomers are administered in combination with one or more other therapeutic agents.
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019165584-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108310377-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109069583-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108586524-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110974954-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109069583-B
priorityDate	2012-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007064945-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9814172-A1
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163904008 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465650839

Total number of triples: 34.